Reproducibility of LSI® HER-2/neu SpectrumOrange(TM) and CEP 17 SspectrumFreen(TM) Dual Color deoxyribonucleic acid Probe Kit: For enumeration of gene amplification in paraffin-embedded specimens; A multicenter clinical validation study

Annals of Clinical and Laboratory Science

Volumn 28, Issue 4, 1998, Pages 215-223

  Masood, Shahla ^a   Bui, Marilyn M ^a   Yung, Jar Fee ^b   Mark, Hon Fong L ^c   Wong, Edith Y ^d   Birkmeier, Jill M ^d   Yang, Su Jan ^d   Hsu, Ping ^d  

^a UNIVERSITY OF FLORIDA HEALTH SCIENCE CENTER   (United States)

^b MERCY HOSPITAL AND MEDICAL CENTER   (United States)

^c BROWN UNIVERSITY   (United States)

^d Vysis   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; BREAST CANCER; CANCER; FLUORESCENCE IN SITU HYBRIDIZATION; GENE EXPRESSION; HUMAN; HUMAN TISSUE; ONCOGENE NEU; PRIORITY JOURNAL; REPRODUCIBILITY; ANALYTICAL EQUIPMENT; BREAST TUMOR; CELL CULTURE; CHEMISTRY; CHROMOSOME 17; CLINICAL TRIAL; DNA PROBE; FLUORESCENCE MICROSCOPY; GENE AMPLIFICATION; GENE EXPRESSION REGULATION; GENETICS; IN SITU HYBRIDIZATION; METABOLISM; METHODOLOGY; MULTICENTER STUDY; PILOT STUDY; PROTO ONCOGENE;

COLORING AGENT; DEXTRAN; DNA; PARAFFIN; SPECTRUM ORANGE;

BREAST NEOPLASMS; CHROMOSOMES, HUMAN, PAIR 17; COLORING AGENTS; DEXTRANS; DNA PROBES; DNA, NEOPLASM; GENE AMPLIFICATION; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, ERBB-2; HUMANS; IN SITU HYBRIDIZATION; MICROSCOPY, FLUORESCENCE; PARAFFIN EMBEDDING; PILOT PROJECTS; REAGENT KITS, DIAGNOSTIC; REPRODUCIBILITY OF RESULTS; TUMOR CELLS, CULTURED;

EID: 0031594939     PISSN: 00917370     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (7)

1. Craft PS, Harris AL. Clinical prognostic significance of tumor angiogenesis and breast cancer. Breast Cancer 1994;8:51.
2. Ciocca DR, Fujimura FK, Tandon AK, Clark GM, Mark C, Lee-Chen G-J, Pounds GW, Vendely P, Owens MA, Pandian MR, McGuire WL. Correlation of HER-2/neu amplification with expression and with other prognostic factors in 1103 breast cancers. J of the National Cancer Institute 1992;84:1279-82.
3. Kerns B-JM, Jordan PA, Huper G, Marks JR, Iglehart JD, Layfield LJ. Assessment of c-erbB-2 amplification by immunohistochemistry in paraffin-embedded breast cancer. Modern Pathology 1993;6:673-8.
4. Slamon DJ, Godolphin W, Jones LA, Holt JA, Wong SG, Keith DE, Levin WJ, Stuart SG, Udove J, Ullrich A, Press MF. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 1989;244:707-12.
5. Allred DC, Clark GM, Molina R, Tandon AK, Schnitt SJ, Gilchrist KW, Osborne CK, Tormey DC, McGuire WL. Overexpression of HER-2/neu and its relationship with other prognostic factors change during the progression of In Situ to invasive breast cancer. Human Pathology 1992;23:974-9.
6. Allred DC, Clark GM, Tandon AK, Molina R, Tormey DC, Osborne CK, Gilchrist KW, Mansour EG, Abeloff M, Eudey L, McGuire WL. HER-2/neu in node-negative breast cancer: prognostic significance of overexpression influenced by the presence of in situ carcinoma. J Clin Oncology 1992;10:599-605.
7. Muss HB, Thor AD, Berry DA, Kute T, Liu ET, Koerner F, Cirrincione CT, Budman DR, Wood WC, Barcos M, Henderson IC. C-erbB-2 expression and response to adjuvant therapy in women with node-positive early breast cancer. N Eng J Med 1994;330:1260-6.